Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin

Hien K Duong, Mikkael A SekeresCleveland Clinic Taussig Cancer Institute, Cleveland, Ohio USAAbstract: As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therape...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hien K Duong, Mikkael A Sekeres
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Treatment Relapsed AML Older Adults Gemtuzumab Ozogamicin Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/fa24b57d3e1c4bbea53e23c8d67b2dc7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa24b57d3e1c4bbea53e23c8d67b2dc7
record_format	dspace
spelling	oai:doaj.org-article:fa24b57d3e1c4bbea53e23c8d67b2dc72021-12-02T02:57:54ZTargeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin1178-1998https://doaj.org/article/fa24b57d3e1c4bbea53e23c8d67b2dc72009-05-01T00:00:00Zhttps://www.dovepress.com/targeted-treatment-of-acute-myeloid-leukemia-in-older-adults-role-of-g-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Hien K Duong, Mikkael A SekeresCleveland Clinic Taussig Cancer Institute, Cleveland, Ohio USAAbstract: As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therapeutic agents with lower toxicity profiles that can be offered to these patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was approved by the US Food and Drug Administration for use as monotherapy in patients 60 years of age and older with relapsed AML. GO consists of a humanized anti-CD33 antibody (hP67.6) which is linked to N-acetyl-γ calicheamicin 1,2-dimethyl hydrazine dichloride. Once the antibody attaches to the surface antigen, it is rapidly internalized. Calicheamicin, a potent enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated.Keywords: acute myeloid leukemia therapy, older adults, gemtuzumab ozogamicinHien K DuongMikkael A SekeresDove Medical PressarticleTreatment Relapsed AMLOlder AdultsGemtuzumab OzogamicinGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 197-205 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Treatment Relapsed AML Older Adults Gemtuzumab Ozogamicin Geriatrics RC952-954.6
spellingShingle	Treatment Relapsed AML Older Adults Gemtuzumab Ozogamicin Geriatrics RC952-954.6 Hien K Duong Mikkael A Sekeres Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
description	Hien K Duong, Mikkael A SekeresCleveland Clinic Taussig Cancer Institute, Cleveland, Ohio USAAbstract: As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therapeutic agents with lower toxicity profiles that can be offered to these patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was approved by the US Food and Drug Administration for use as monotherapy in patients 60 years of age and older with relapsed AML. GO consists of a humanized anti-CD33 antibody (hP67.6) which is linked to N-acetyl-γ calicheamicin 1,2-dimethyl hydrazine dichloride. Once the antibody attaches to the surface antigen, it is rapidly internalized. Calicheamicin, a potent enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated.Keywords: acute myeloid leukemia therapy, older adults, gemtuzumab ozogamicin
format	article
author	Hien K Duong Mikkael A Sekeres
author_facet	Hien K Duong Mikkael A Sekeres
author_sort	Hien K Duong
title	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
title_short	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
title_full	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
title_fullStr	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
title_full_unstemmed	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
title_sort	targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/fa24b57d3e1c4bbea53e23c8d67b2dc7
work_keys_str_mv	AT hienkduong targetedtreatmentofacutemyeloidleukemiainolderadultsroleofgemtuzumabozogamicin AT mikkaelasekeres targetedtreatmentofacutemyeloidleukemiainolderadultsroleofgemtuzumabozogamicin
_version_	1718402079064588288

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin

Ejemplares similares